.95 for insulin lispro, human insulin, and insulin aspart, respectively.21 In addition, 50 precipitation was reported at pH 5.86 for insulin aspart and pH 6.64 for insulin glulisine.22 In both studies, the highest resistance to isoelectric precipitation was reported with insulin aspart, with intermediate resistance observed for human insulin, and lowest resistance for insulin lispro and insulin glulisine. The low degree of precipitation seen with insulin aspart could possibly be as a result of its lower pH along with the larger volume of acid essential to induce isoelectric precipitation.22 The stability of insulin aspart for use in CSII was studied by Senstius and coauthors18 (Table two). They assessed two numerous insulin aspart of distinct age stored up to 7 days at 37 2 in reservoirs and exposed to continuous each day mechanical agitation (30 three oscillations/min, two 0.five cm amplitude displacement).18 Under CSII situations, insulin aspart maintained its potency (99 ), and no significant variations in pH, transformation merchandise, or preservatives had been observed following 7 days, compared with reference values. Furthermore, the solutions have been fibril and precipitatefree. The authors concluded that stability was maintained irrespective of the age of the batch (freshly manufactured versus finish of shelf life). Working with identical conditions (37 2 ; 30 oscillations/min, 2 cm amplitude), yet another study compared the stability of insulin aspart with insulin glulisine at distinct flow prices (0.three and 0.9 U/h) more than 10 days.19 Test samplesStability and TemperatureSensitivity of Insulin AnalogsIn Vitro FindingsJ Diabetes Sci Technol Vol 7, Challenge 6, Novemberwww.jdst.orgJ Diabetes Sci Technol Vol 7, Problem 6, NovemberStability and Performance of RapidActing Insulin Analogs Utilised for Continuous Subcutaneous Insulin Infusion: A Systematic ReviewTable two. Stability of RapidActing Insulin Analogs Exposed to High Temperature and Mechanical Agitation in CSII In Vitro StudiesaStudy (initially author) Lougheed16 RAI ILis Length (days) two Temp ( ) 37 Agitation (oscillations/min) Stationary Basal/bolus infusion rate 0.2-Hydroxycyclopent-2-en-1-one site 5 U/h 6 U/bolus 0.8 U/h 6 U/bolus 0.1 U/h No boli 0.3 U/h No boli 0.9 U/h No boli Device MiniMed 504 HTRON V100 MiniMed 507c HTRONplus DTRON CSII MiniMed 508 MiniMed 508 MiniMed 508 MiniMed 508 MiniMed 508 Solo MicroPump 6 37 35 0.2-(2-Bromoethyl)oxirane Formula 6 U/h five U/bolus Solo MicroPump Solo MicroPump Solo MicroPump 6 37 35 0.PMID:33634485 three U/h two.five U/bolus Solo MicroPump Solo MicroPump 14 37 100 0.8 U/h 6 U/bolus Purity ( ) Deamidation/ isomerization Handle Lougheed16 ILis 0.58 0.eSamples analyzed R, P R, P R, P R, P R, P R R, P R, P R, P R, P R, P R, P R, P R, P R, P R, P R, PHMWP ( ) Manage 0.20 0.23 0.2 0.two 0.3 0.1 0.20d 0.30d 0.dPotency ( )bObserved 0.26 (R) 0.26 (R) 0.3 (P) 0.three (P) 0.five (P) 0.1 (R) 0.40 (P) 0.80 (P) 0.30 (P) 0.60 (P)Control 100.1 102.3 9505 9505 9505 99.2 ND ND ND ND 100d 100d 100d 100d 100d 100d 9505dObservedb 103.6 (P) 103.9 (P) 95.005 (P) 95.005 (P) 95.005 (P) 99.two (R) ND ND ND ND 9505 (P and R) 9505 (P and R) 9505 (P and R) 9505 (P and R) 9505 (P and R) 9505 (P and R) 9505 (P) pH Manage 7.0.8 7.0.eight Observedb 7.0.eight (P) 7.0.8 (P) ContinuedDeFelippisILiscSenstiusIAsp IAsp73730SenstiusIGlu IAsp IGlu IAsp IGlu ILis0.30d 0.1.2d 0.4.5d 0.1.2d 0.1.2d 0.five.6d 0.1.2d 0.4d0.3.four (P) 0.2.3 (R) 0.eight.9 (P) 0.eight.9 (R) 0.3.4 (P) 0.two.3 (R) 0.two.3 (P) 0.2.3 (R) 1.0.1 (P) 1.0.1 (R) 0.1.two (P) 0.2.3 (R) 0.three.six (P)1600 Senesh20 Sharrowwww.jdst.orgIAsp IGlu ILis ILisMiniMed ParadigmPreservative content material (mg/ml) Relate.